EFFICACY AND SAFETY OF CURCUMA LONGA EXTRACT IN THE TREATMENT OF OSTEOARTHRITIS: A SYSTEMATIC REVIEW
Objective: Osteoarthritis (OA) is a chronic disease caused by inflammation of the tissue and bony structure of the joint, which affects more than 235 million people worldwide. Due to the adverse effects caused by the long-term use of standard treatment of OA, the attempt to find natural remedies to treat chronic diseases continues to rise. Curcuma longa is known to have anti-inflammatory effects, which may impact the pathophysiology of OA. While many randomized controlled trials show the efficacy of Curcuma longa extract in the treatment of OA, there has been no comprehensive review of this evidence.
Methods: We systematically searched PubMed, Cochrane, Scopus, ProQuest, EBSCOhost, and ScienceDirect for randomized controlled trials that evaluated Curcuma longa extract (CE extract) vs. control (placebo or other therapy). Three trials were identified. Data were then extracted from the studies and summarized descriptively.
Results: Across all trials, Curcuma longa therapy was proven to reduce Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores significantly compared to the control group. Adverse effects were less likely to appear in patients treated with Curcuma longa extract compared to other groups.
Conclusion: CL extract is beneficial as an alternative medication for OA treatment, shown by the reduced scores of the Visual Analog Scale (VAS) and WOMAC in all studies we reviewed.
2. Ali SA, Kokorelias KM, MacDermid JC, Kloseck M. Education and social support as key factors in osteoarthritis management programs: a scoping review. Arthritis 2018;2018:1–8.
3. Maxine Ross S. Effects of Curcuma longa extracts compared with ibuprofen for reduction of pain and functional improvement in patients with knee osteoarthritis. Holist Nurs Pr 2016;30:183–6.
4. Van Tunen JAC, Peat G, Bricca A, Larsen LB, Søndergaard J, Thilsing T, et al. Association of osteoarthritis risk factors with knee and hip pain in a population-based sample of 29–59 y olds in denmark: a cross-sectional analysis. BMC Musculoskelet Disord 2018. Available from: https://bmcmusculoskeletdisord. biomedcentral.com/articles/10.1186/s12891-018-2183-7 [Last accessed on 02 Oct 2018]
5. Fransen M, Bridgett L, March L, Hoy D, Penserga E, Brooks P. The epidemiology of osteoarthritis in Asia: osteoarthritis in Asia. Int J Rheum Dis 2011;14:113–21.
6. Permatasari Y, Zulqarnain N, Sukmaningtyas H, Suntoko B. Correlations between osteoarthritis grading in femorotibial joint (Kellgren Lawrence) with cartilage defects grading. Indones J Rheumatol 2016;8:23–5.
7. Madhu K, Chanda K, Saji MJ. Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. Inflammopharmacology 2013;21:129–36.
8. Srivastava S, Saksena AK, Khattri S, Kumar S, Dagur RS. Curcuma longa extract reduces inflammatory and oxidative stress biomarkers in osteoarthritis of knee: a four-month, double-blind, randomized, placebo-controlled trial. Inflammopharmacology 2016;24:377–88.
9. Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis. J Altern Complement Med 2009;15:891–7.
10. Pinsornsak P, Niempoog S. The efficacy of Curcuma longa extract as an adjuvant therapy in primary knee osteoarthritis: a randomized control trial. J Med Assoc Thai 2012;95:S51–8.
11. Jackson JK, Higo T, Hunter WL, Burt HM. The antioxidants curcumin and quercetin inhibit inflammatory processes associated with arthritis. Inflamm Res 2006;55:168–75.
12. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264–9, W64.
13. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1–12.
14. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Br Med J 2011;343:d5928.
15. Klimek L, Bergmann KC, Biedermann T, Bousquet J, Hellings P, Jung K, et al. Visual analogue scales (VAS): measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care: position paper of the german society of allergology (AeDA) and the german society of allergy and clinical immunology (DGAKI), ENT section, in collaboration with the working group on clinical immunology, allergology and environmental medicine of the german society of otorhinolaryngology, head and neck surgery (DGHNOKHC). Allergo J Int 2017;26:16–24.
16. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: visual analog scale for pain (VAS Pain), numeric rating scale for pain (NRS Pain), McGill pain questionnaire (MPQ), short-form mcgill pain questionnaire (SF-MPQ), chronic pain grade scale (CPGS), short form-36 bodily pain scale SF. Arthritis Care Res 2011;63(S11):S240–52.
17. Ebrahimzadeh MH, Makhmalbaf H, Birjandinejad A, Keshtan FG, Hoseini HA, Mazloumi SM. The western ontario and mcmaster universities osteoarthritis index (WOMAC) in persian-speaking patients with knee osteoarthritis. Arch Bone Jt Surg 2014;2:57–62.
18. Perkins K, Sahy W, Beckett RD. Efficacy of Curcuma for treatment of osteoarthritis. J Evid-Based Complement Altern Med 2017;22:156–65.
This work is licensed under a Creative Commons Attribution 4.0 International License.